Condition: Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck · Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
The main objective of this research is to increase the life expectancy of patients with advanced mouth and throat cancer, by adding avelumab to the standard TPEx treatment. All participants in this research will receive the same treatment which will take place in two phases: * 1st phase chemotherapy + immunotherapy: standard reference treatment (Docetaxel + cisplatin or carboplatin + cetuximab) * 2nd phase immunotherapy: cetuximab combined with avelumab which is the treatment under study.
This description comes directly from the study's public registry record.
Caroline EVEN, MD · 0142116597 · caroline.even@gustaveroussy.fr
Adeline PECHERY · 0649210607 · adeline.pechery@gortec.fr
Always discuss trial participation with your own doctor first.
| Institut de Cancérologie de Lorraine | Vandœuvre-lès-Nancy, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06640725